Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee

M. Angles; John B. Bossaer

Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee

Department of Pharmacy Practice

Research output: Contribution to conference › Presentation

Abstract

Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.

Original language	American English
State	Published - Mar 1 2012
Event	Hematology Oncology Pharmacy Association Annual Meeting - Austin, TX Duration: Mar 1 2015 → …

Conference

Conference	Hematology Oncology Pharmacy Association Annual Meeting
Period	3/1/15 → …

Keywords

cetuximab-related hypersensitivity

Disciplines

Pharmacy and Pharmaceutical Sciences

Cite this

@conference{1c34642d3e8b42a4914d4494ecb6a214,

title = "Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee",

abstract = " Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22\% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3\%.",

keywords = "cetuximab-related hypersensitivity",

author = "M. Angles and Bossaer, \{John B.\}",

year = "2012",

month = mar,

day = "1",

language = "American English",

note = "Hematology Oncology Pharmacy Association Annual Meeting ; Conference date: 01-03-2015",

}

TY - CONF

T1 - Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee

AU - Angles, M.

AU - Bossaer, John B.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.

AB - Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.

KW - cetuximab-related hypersensitivity

UR - https://dc.etsu.edu/etsu-works/2357

M3 - Presentation

T2 - Hematology Oncology Pharmacy Association Annual Meeting

Y2 - 1 March 2015

ER -

Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee

Abstract

Conference

Keywords

Disciplines

Other files and links

Cite this